



DALE CAPITAL GROUP LIMITED AND ITS SUBSIDIARIES (“Dale” or the “Company” or the “Group”) UNAUDITED ABRIDGED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED 31 MAY 2023

(Incorporated by way of continuation in the British Virgin Islands) | (Registration number: B.V.I No: 1443428)
SEM Code: DCPL.N0000 | ISIN: MU0227N00002

STATEMENT OF COMPREHENSIVE INCOME

	The Group			The Company		
	Unaudited for the three months ended 31 May 2023 USD	Unaudited for the three months ended 31 May 2022 USD	Audited for the year ended 28 February 2023 USD	Unaudited for the three months ended 31 May 2023 USD	Unaudited for the three months ended 31 May 2022 USD	Audited for the year ended 28 February 2023 USD
REVENUE						
Sale of Goods	-	-	34,197	-	-	-
Other income	-	-	3,773,528	-	-	-
	-	-	3,807,725	-	-	-
Cost of Goods Sold	-	-	(115,345)	-	-	-
Administrative expenses	(120,005)	-	(146,986)	-	-	(70,818)
Operating expenses	(1,306,488)	-	(4,878,224)	-	-	(4,270,283)
Loss from operations	(1,426,493)	-	(1,332,830)	-	-	(4,341,101)
Finance costs	-	-	(128,846)	-	-	(118,310)
Impairment loss	-	-	(376,779)	-	-	(376,779)
Loss/ profit on disposal of PPE	-	-	(3,938)	-	-	-
Loss before taxation	(1,426,493)	-	(1,842,393)	-	-	(4,836,190)
Income tax	-	-	-	-	-	-
Loss for the period after tax	(1,426,493)	-	(1,842,393)	-	-	(4,836,190)
Other comprehensive income	-	-	-	-	-	-
Total comprehensive (loss)/income for the period	(1,426,493)	-	(1,842,393)	-	-	(4,836,190)
Loss attributable to:						
Shareholders of the parent	(1,426,493)	-	(1,842,393)	-	-	(4,836,190)
Non-controlling interest	-	-	-	-	-	-
(Loss)/Profit Per Share	(0.0049)	-	(0.0063)	-	-	(0.0166)
Dividend Per Share	-	-	-	-	-	-

STATEMENT OF FINANCIAL POSITION

	The Group		The Company	
	Unaudited as at 31 May 2023 USD	Audited as at 28 February 2023 USD	Unaudited as at 31 May 2023 USD	Audited as at 28 February 2023 USD
ASSETS				
Non-current assets				
Investment in subsidiaries	-	-	904,687	904,687
Property, Plant and Equipment	62,187	61,312	-	-
Intangible assets	250	246	-	-
Available-for-sale financial assets	-	-	-	-
Biological Assets	-	-	-	-
Investment at fair value through profit or loss	-	-	-	-
Loans receivable	169,466	167,082	-	-
	231,903	228,640	904,687	904,687
Current assets	1,245,937	1,219,337	1,099,390	1,099,390
TOTAL ASSETS	1,477,840	1,447,977	2,004,077	2,004,077
EQUITY AND LIABILITIES				
Stated capital	12,219,919	12,219,919	12,219,919	12,219,919
Reserves	(11,898,301)	(11,918,762)	(10,703,767)	(10,703,767)
Shareholders' interest	321,618	301,157	1,516,152	1,516,152
Non-controlling interest	-	-	-	-
Total equity	321,618	301,157	1,516,152	1,516,152
Non-current liabilities	378,076	376,694	279,853	279,853
Current liabilities	778,146	770,126	208,072	208,072
TOTAL EQUITY AND LIABILITIES	1,477,840	1,447,977	2,004,077	2,004,077
Net Asset Value per share:	0.001	0.001	0.005	0.005
Weighted average Number of shares in issue*	292,143,232	292,143,232	292,143,232	292,143,232

NOTES TO THE ACCOUNTS

No shares were issued during the period ended 31 May 2023. The weighted average number of shares in issue has been used to calculate the Net Asset Value per Share. As at 31 May 2023, the number of shares in issue was 292,143,232.

The Unaudited Abridged Financial Statements for the three months ended 31 May 2023 (“Unaudited Abridged Financial Statements”) are presented in accordance with IAS 34 (Interim Financial Reporting). The accounting policies and methods of computation are consistent with those applied in the audited annual financial statements for the year ended 28 February 2023.

STATEMENT OF CASH FLOWS

	The Group		The Company	
	Unaudited for the three months ended 31 May 2023 USD	Audited Year Ended 28 February 2023 USD	Unaudited for the three months ended 31 May 2021 USD	Audited Year Ended 28 February 2021 USD
Net cash flow generated from / (used in) operating activities	(1,426,493)	3,522,889	-	(419,304)
Net cash flow used in investing activities	-	400,000	-	400,000
Net cash flow from financing activities	1,426,493	(3,949,997)	-	18,257
Net (decrease) / increase in cash and cash equivalents	-	(27,108)	-	(1,047)
Cash and cash equivalents at beginning of the period	(105,186)	(78,078)	22	1,069
Effect of exchange rate difference	(1,502)	-	-	-
Cash and cash equivalents at end of the year	(106,688)	(105,186)	22	22

STATEMENT OF CHANGES IN EQUITY

THE GROUP

Stated capital USD	Revaluation and other reserves USD	Minority Interests USD	Total USD
12,219,919	(7,524,990)	19,407	4,714,336
-	(2,551,379)	(19,407)	(2,570,786)
-	(1,842,393)	-	(1,842,393)
12,219,919	(11,918,762)	-	301,157
-	1,446,954	-	1,446,954
-	(1,426,493)	-	(1,426,493)
12,219,919	(11,898,301)	-	321,618

THE COMPANY

12,219,919	(5,867,577)	-	6,352,342
-	-	-	-
-	(4,836,190)	-	(4,836,190)
12,219,919	(10,703,767)	-	1,516,152
-	-	-	-
-	-	-	-
12,219,919	(10,703,767)	-	1,516,152

The Statement of direct and Indirect interests of each officer of the Company, pursuant to rule 8(2)(m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007 is available free of charge at the administrative office of the Company. The Unaudited Abridged Financial Statements are issued pursuant to Listing Rule 15.44 of the Stock Exchange of Mauritius Ltd and the Mauritian Securities Act 2005. Copies of the Unaudited Abridged Financial Statements are available free of charge at the administrative office of the Company, at St Antoine Industrial Zone, Goodlands, Mauritius.

The Board of Dale accepts full responsibility for the accuracy of the information contained in this announcement. These Unaudited Abridged Financial Statements were approved by the Board on 13 November 2023.

By order of the Board
13 November 2023